Last update 01 Nov 2024

BGT-007

Overview

Basic Info

Drug Type
T-lymphocyte cell therapy
Synonyms
+ [1]
Target-
Mechanism
T lymphocyte replacements
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]
Active Indication
Intestinal preparationPancreatic CancerGastrointestinal Neoplasms+ [2]
Inactive Indication-
Originator Organization
Guangzhou Bairui Biomedical Technology Co., Ltd.Guangzhou BioSyngen Co., Ltd.
Active Organization
Affiliated Hospital of Xuzhou Medical UniversityAffiliated Hospital of Xuzhou Medical UniversityBioSyngen Pte Ltd.BioSyngen Pte Ltd.StartupGuangzhou Bairui Biomedical Technology Co., Ltd.
Inactive Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with BGT-007
NCT06645301 / Not yet recruitingEarly Phase 1
Exploratory Clinical Study Initiated by Researchers on the Safety and Preliminary Efficacy of BGT007 in Treating Patients with Recurrent/refractory Gastrointestinal Malignancies
NCT06104215 / RecruitingEarly Phase 1IIT
Clinical Study on the Safety and Initial Efficacy of BGT007H Cell Therapy in Patients With Recurrent/Metastatic Refractory Digestive Tract Tumors
NCT06104241 / RecruitingEarly Phase 1IIT
Clinical Study on the Safety and Initial Efficacy of BGT007 Cell Therapy in Patients With Recurrent/Metastatic Refractory Digestive Tract Tumors
100 Clinical Results associated with BGT-007
Login to view more data
100 Translational Medicine associated with BGT-007
Login to view more data
100 Patents (Medical) associated with BGT-007
Login to view more data
100 Deals associated with BGT-007
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Intestinal preparationPhase 1-
BioSyngen Pte Ltd.BioSyngen Pte Ltd.Startup
30 Nov 2024
Pancreatic CancerPhase 1-
BioSyngen Pte Ltd.BioSyngen Pte Ltd.Startup
30 Nov 2024
Gastrointestinal NeoplasmsPhase 1
CN
BioSyngen Pte Ltd.BioSyngen Pte Ltd.Startup
09 Oct 2023
Nasopharyngeal Cancer, RecurrentPhase 1
CN
Affiliated Hospital of Xuzhou Medical UniversityAffiliated Hospital of Xuzhou Medical University
30 Dec 2022
Nasopharyngeal CarcinomaPhase 1
CN
Affiliated Hospital of Xuzhou Medical UniversityAffiliated Hospital of Xuzhou Medical University
30 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free